Search Results
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
applications across multiple high-need genetic diseases. I am particularly excited by the potential of Dualase® genome editors to provide a durable, gene-level benefit for patients with diseases such as amyotrophic lateral sclerosis (ALS), where meaningful disease-modifying therapeutic options remain
More news about: Specific Biologics Inc.
Dec 16, 2025, 09:06 ET Orsini Names Ashley Keller as Chief People Officer
thrive."About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Dec 16, 2025, 06:07 ET New Modeling Approach Sheds Light on Rare Gut Disease
realistic model of HSCR in mice. Instead of completely knocking out either gene, the researchers made different combinations of mice in which one or both genes were either still partially functional or in which just one copy of the gene was deleted.In the combination that best replicated the symptoms
More news about: NYU Langone Health System
Dec 15, 2025, 17:31 ET Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight
Gene Therapies for Cardiomyopathies Market SummaryThe market size for gene therapies for cardiomyopathies in the leading markets is expected to grow significantly by 2034.The United States accounted for the highest gene therapies for cardiomyopathies treatment
More news about: DelveInsight Business Research, LLP
Dec 15, 2025, 16:30 ET The Inner Circle acknowledges, Melvin Colón as a Pinnacle Professional Member Inner Circle of Excellence
market. Mr. Colón is a licensed chemist with a proven track record of success across the pharmaceutical, biotechnology, including cell and gene therapy, biosimilars, and medical device industries, including combination products. His expertise includes Quality Assurance Management, Quality Control,
More news about: The Inner Circle
Dec 15, 2025, 16:19 ET ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
disease-modifying therapy to people living with Alzheimer's around the world.""Erik Wallstroem, Global Head of Multiple Sclerosis, Neurology and Gene Therapy Development, Sanofi, commented: 'ADEL's innovative approach to targeting tau acetylation offers a promising and differentiated mechanism for
More news about: ADEL, Inc.
Dec 15, 2025, 14:58 ET Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
Cocktail assayThe VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status. VENTANA HER2 Dual ISH helps identify breast cancer patients eligible for personalized treatment with HER2-targeted therapies. The VENTANA HER2
More news about: Roche
Dec 15, 2025, 13:00 ET Thatch and MyOme Launch First Genomics Solution in Thatch's Personalized Benefits Marketplace
positive ROI."What's AvailableThatch members can now access MyOme Proactive Health, which includes:Single-Gene Risk Insights: Identify clinically actionable variants that impact health and disease risk.Medication Response Insights (Pharmacogenomics):
More news about: MyOme, Inc
Dec 15, 2025, 11:01 ET UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE NAMES DISTINGUISHED SCIENTIST AND ACADEMIC LEADER GERALD M. WILSON, PHD, AS CHAIR OF THE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
42, Dr. Wilson's research has advanced understanding of the mechanisms of RNA-protein interactions; this includes their roles in post-transcriptional gene regulation and dysregulation of these processes in cancer and cardiovascular disease. His work has been funded by major grants from the National Institutes
More news about: University of Maryland Medical Center
Dec 15, 2025, 09:05 ET Pivot Bio Announces Additions to Senior Management
During her time at Calyxt, she held several leadership roles across R&D operations and research, and she contributed to the launch of the first gene-edited food product on the market — Calyno high-oleic soybean oil. Earlier in her career, Liberatore completed postdoctoral work at the USDA Cereal
More news about: Pivot Bio, Inc
Dec 15, 2025, 08:38 ET Chonnam National University Uncovers a New Molecular Target of Obesity
They found that RFP interacts directly with PPAR-γ, the master transcription factor (a special protein that governs adipocyte differentiation through gene regulation). By modulating PPAR-γ transcriptional activity, RFP increases the expression of fat cell-generating genes such as AP2 and adiponectin which
More news about: Chonnam National University
Dec 15, 2025, 08:02 ET Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Non-Profit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US
rare and complex genetic diseases, today announced the signing of a Memorandum of Understanding (MoU) to facilitate US commercial access to an ex vivo gene therapy for the treatment of Wiskott-Aldrich syndrome, which was developed by Fondazione Telethon and has just received
More news about: Orphan Therapeutics Accelerator; Fondazione Telethon
Dec 15, 2025, 08:01 ET Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
Disease | ClinicalTrials.gov)About Menkes DiseaseMenkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. The minimum birth prevalence for Menkes disease is believed to be 1 in 34,810 live male births, and potentially
More news about: Sentynl Therapeutics
Dec 15, 2025, 08:00 ET Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
94102Panel ParticipationSession Title: Engineering the Future: Advances in Cell and Gene TherapiesDescription: Explore cutting-edge advances in cell and gene therapies that reshape the treatment landscape and create new investment opportunities. This session highlights
More news about: Diakonos Oncology
Dec 15, 2025, 08:00 ET Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease
paradigm shift in the treatment of genetic diseases, while addressing key limitations associated with approved therapeutic approaches and investigational gene therapies."Orphan Drug Designation for ISP-002 is an important milestone for our MPS II program and further validates the potential of our engineered
More news about: Immusoft
Dec 15, 2025, 08:00 ET Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
neurological conditions. By leveraging a proprietary, Nobel Prize-winning iPSC platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's lead candidate, RNDP-001, is in Phase 1 clinical development for moderate to moderate-severe
More news about: Kenai Therapeutics/BIOCOM
Dec 15, 2025, 07:00 ET Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations.
More news about: Vanda Pharmaceuticals Inc.
Dec 15, 2025, 01:00 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Dec 15, 2025, 00:49 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
the 162 patients with BRCA2 gene alteration(s) who received AKEEGA® in AMPLITUDE, 40% of patients were less than 65 years, 36% of patients were 65 years to 74 years, and 23% were 75 years and over.Of the 113 patients with BRCA gene alteration(s) who received AKEEGA®
More news about: Johnson & Johnson
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 08:35 ET Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
RAG-18RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression in muscle cells via RNAa mechanism. The utrophin protein encoded by the UTRN gene is structurally and functionally similar to dystrophin, and its upregulation could potentially serve as
More news about: Ractigen Therapeutics
Dec 11, 2025, 10:15 ET Cell Therapy Technologies Market worth $7.91 billion by 2030 | MarketsandMarkets™
the growth of the cell therapy technologies market include the increased funding and investment in cell therapy and the growing size of the cell and gene therapy pipeline. Furthermore, the growing adoption of automation in manufacturing processes enhances efficiency and scalability, and the growing demand
More news about: MarketsandMarkets
Dec 11, 2025, 10:06 ET ASCAP UNWRAPS 2025 NEW CLASSIC HOLIDAY TOP 10 WITH HITS FROM MARIAH CAREY, KELLY CLARKSON, JUSTIN BIEBER, KATY PERRY, JIMMY FALLON, MEGHAN TRAINOR AND MORE
by Ray Evans and Jay Livingston (1950)"Feliz Navidad" by José Feliciano (1970)"Here Comes Santa Claus (Down Santa Claus Lane)" by Gene Autry and Oakley Haldeman (1947)"Deck the Halls" (Nat King Cole version), arranged by Nat King Cole and Leland Gillette (1960)"This
More news about: ASCAP - American Society of Composers, Authors and Publishers
Dec 11, 2025, 09:29 ET The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer
treatment approach that combines elacestrant with everolimus in a broad group of patients with advanced ER+/HER2- breast cancer and mutations in the ESR1 gene.About MEDSIREstablished in 2012, MEDSIR distinguishes itself by its close collaboration with strategic partners to drive innovation
More news about: MEDSIR